Progress in adjuvant systemic therapy for breast cancer.

Auteurs : Pondé NF, Zardavas D, Piccart-Gebhart M
Année : 2019
Journal : Nat Rev Clin Oncol
Volume : 16
Pages : 27-44

Mammaprint™: a comprehensive review.

Auteurs : Brandão M, Pondé N, Piccart-Gebhart M
Année : 2019
Journal : Future Oncol
Volume : 15
Pages : 207-224

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Auteurs : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Année : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 86-94

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.(autors : Early Breast Cancer Trialists'Collaborative Group)

Auteurs : Early Breast Cancer Trialists Collaborative Group, + collaborators (among others :, Piccart-Gebhart M
Année : 2018
Journal : Lancet Oncol
Volume : 19
Pages : 27-39

Long-Term Clinical Outcome and Survivorship Issues of High Grade Bone Sarcomas

Auteurs : Closset C, Ameye L, Gebhart M, de Saint-Aubain de Somerhausen N, Beauvois S, Awada A, Piccart-Gebhart M, Gil T
Année : 2018
Journal : Int J cancer and oncology
Volume : 5(1)
Pages : 26-34

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Auteurs : Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber Rd, Goldhirsch A, Regan MM, + collaborators (among others :, Piccart-Gebhart M
Année : 2018
Journal : N Engl J Med
Volume : 379
Pages : 122-137

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.

Auteurs : Maurer C, Tulpin L, Moreau M, Dumitrescu C, de Azambuja E, Paesmans M, Nogaret JM, Piccart-Gebhart M, Awada A
Année : 2018
Journal : ESMO Open
Volume : 3
Pages : e000440

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

Auteurs : Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart-Gebhart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A
Année : 2018
Journal : Lancet Oncol
Volume : 19
Pages : e459-e469

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

Auteurs : Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, OConnor D, Oliver K, Piault-Louis E, Piccart-Gebhart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C
Année : 2018
Journal : Clin Trials
Volume : 15
Pages : 624-630

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations.

Auteurs : Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart-Gebhart M, Rothé F, Sotiriou C
Année : 2018
Journal : NPJ Breast Cancer
Volume : 4
Pages : 23

Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.

Auteurs : Sidibe FM, Traore Z, Georgala A, Kanab R, Larsimont D, Awada A, Piccart-Gebhart M
Année : 2018
Journal : Bull Cancer
Volume : 105
Pages : 842-846

The legacy of Thomas Tursz: building a leading comprehensive cancer center in Europe.

Auteurs : Soria JC, Baselga J, Piccart-Gebhart M
Année : 2018
Journal : Ann Oncol
Volume : 29
Pages : 1887-1888

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Auteurs : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Année : 2018
Journal : Ann Oncol
Volume : 29(8)
Pages : 1777-1783

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C
Année : 2018
Journal : JAMA Oncol
Volume : 4
Pages : e181564

Neoadjuvant treatment: the future of patients with breast cancer.

Auteurs : Reyal F, Hamy AS, Piccart-Gebhart M
Année : 2018
Journal : ESMO Open
Volume : 3
Pages : e000371

Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Auteurs : Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart-Gebhart M
Année : 2018
Journal : Cancer Treat Rev
Volume : 67
Pages : 10-20

PUBLISHED ERRATUM (2016): PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Année : 2018
Journal : Ann Oncol
Volume : 29
Pages : 2151

Reply to ESMO-MCBS v1.1: Statistical and Patient Relevant Shortcomings" by R. Emprechtinger et al."

Auteurs : Cherny NI, Dafni U, Piccart-Gebhart M, Latino NJ, Douillard JY, Bogaerts J, Karlis D, Zygoura P, Pentheroudakis G, Tabernero J, Zielinski C, de Vries EGE
Année : 2018
Journal : Ann Oncol
Volume : 29(5)
Pages : 1335-1338

Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.

Auteurs : Desmedt C, Demicheli R, Fornili M, Bachir I, Duca M, Viglietti G, Berlière M, Piccart-Gebhart M, Sotiriou C, Sosnowski M, Forget P, Biganzoli E
Année : 2018
Journal : J Natl Cancer Inst
Volume : 110(10)
Pages : 1115-1122

erratum :Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2018
Journal : Ann Oncol
Volume : 29
Pages : 2152